1. Why now? Given BrainChip’s declining fundamentals, wouldn’t it be better to strengthen the business first before attempting a U.S. listing?
2. Is this move about access to capital, or is it a way to escape the scrutiny of ASX investors?
3. If BrainChip struggles to gain investor confidence in Australia, why do you believe U.S. investors will react differently?
4. What evidence do you have that BrainChip would attract greater institutional interest in the U.S., despite its current
5. Does the company have enough revenue growth and profitability potential to justify a U.S. listing, or is this simply a liquidity play?
6. BrainChip’s fundamentals are currently weak—how will a U.S. listing change that? Are you expecting a valuation boost simply because of a different market?
7. Has BrainChip engaged with U.S. investors already? If so, what feedback have you received?
8. Are you concerned that the U.S. market, particularly Nasdaq, could be even more unforgiving to BrainChip’s financial struggles than the ASX?
9. What contingency plans do you have if the move does not result in improved market confidence or liquidity?
10. Are you prepared for the potential backlash from Australian retail investors who may feel abandoned by this decision?
11. How will this impact BrainChip’s ability to raise capital in the short term? If the fundamentals don’t improve, will a U.S. listing really make fundraising easier?
12. Does this move suggest that management has failed to turn the company around and is looking for an exit strategy?
13. How much of this decision is being driven by leadership incentives rather than actual long-term shareholder value?
14. Will there be any changes in executive compensation or leadership structure as part of this move?
BRN Price at posting:
20.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)